Pocapavir

Pocapavir
Clinical data
Other names	V-073
Identifiers
	IUPAC name 1,3-dichloro-2-{[4-[(2-chloro-4-methoxyphenoxy)methyl]phenyl]methoxy}benzene;
CAS Number	146949-21-5;
PubChem CID	1455;
DrugBank	DB17736;
UNII	4ILA3VOV97;
ChEMBL	ChEMBLCHEMBL1235858;
CompTox Dashboard (EPA)	DTXSID00163548 ;
Chemical and physical data
Formula	C21H17Cl3O3
Molar mass	423.71 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=C(C=C1)OCC2=CC=C(C=C2)COC3=C(C=CC=C3Cl)Cl)Cl;
	InChI InChI=1S/C21H17Cl3O3/c1-25-16-9-10-20(19(24)11-16)26-12-14-5-7-15(8-6-14)13-27-21-17(22)3-2-4-18(21)23/h2-11H,12-13H2,1H3; Key:XXMDDBVNWRWNCW-UHFFFAOYSA-N;

Pocapavir (V-073, SCH48973) is an antiviral drug which acts as a capsid inhibitor. It was developed for the treatment of enterovirus infections, including diseases such as polio and coxsackievirus, and also has activity against parechoviruses.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

References

^ Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E (July 1997). "Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes". Structure. 5 (7): 961–978. doi:10.1016/s0969-2126(97)00249-9. PMID 9261087.
^ De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J (April 2008). "Potential use of antiviral agents in polio eradication". Emerging Infectious Diseases. 14 (4): 545–551. doi:10.3201/eid1404.070439. PMC 2570929. PMID 18394270.
^ McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR (November 2014). "Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication". The Journal of Infectious Diseases. 210: S447–S453. doi:10.1093/infdis/jiu043. PMID 25316866.
^ Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ (January 2015). "First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis". The Pediatric Infectious Disease Journal. 34 (1): 52–54. doi:10.1097/INF.0000000000000497. PMID 25229269.
^ Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M (February 2017). "Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model". The Journal of Infectious Diseases. 215 (3): 335–343. doi:10.1093/infdis/jiw542. PMC 5393058. PMID 27932608.
^ Harik N, DeBiasi RL (April 2018). "Neonatal nonpolio enterovirus and parechovirus infections". Seminars in Perinatology. 42 (3): 191–197. doi:10.1053/j.semperi.2018.02.007. PMID 29526382.
^ Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B (May 2020). "Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir". The Pediatric Infectious Disease Journal. 39 (5): 435–437. doi:10.1097/INF.0000000000002584. PMID 32150007.
^ Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR (September 2021). "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers". Antimicrobial Agents and Chemotherapy. 65 (10): e0102921. doi:10.1128/AAC.01029-21. PMC 8448163. PMID 34370575.
^ Tomatis Souverbielle C, Erdem G, Sánchez PJ (June 2023). "Update on nonpolio enterovirus and parechovirus infections in neonates and young infants". Current Opinion in Pediatrics. 35 (3): 380–389. doi:10.1097/MOP.0000000000001236. PMID 36876331.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E (July 1997). "Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes". Structure. 5 (7): 961–978. doi:10.1016/s0969-2126(97)00249-9. PMID 9261087.

[2] De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J (April 2008). "Potential use of antiviral agents in polio eradication". Emerging Infectious Diseases. 14 (4): 545–551. doi:10.3201/eid1404.070439. PMC 2570929. PMID 18394270.

[3] McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR (November 2014). "Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication". The Journal of Infectious Diseases. 210: S447–S453. doi:10.1093/infdis/jiu043. PMID 25316866.

[4] Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ (January 2015). "First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis". The Pediatric Infectious Disease Journal. 34 (1): 52–54. doi:10.1097/INF.0000000000000497. PMID 25229269.

[5] Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M (February 2017). "Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model". The Journal of Infectious Diseases. 215 (3): 335–343. doi:10.1093/infdis/jiw542. PMC 5393058. PMID 27932608.

[6] Harik N, DeBiasi RL (April 2018). "Neonatal nonpolio enterovirus and parechovirus infections". Seminars in Perinatology. 42 (3): 191–197. doi:10.1053/j.semperi.2018.02.007. PMID 29526382.

[7] Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B (May 2020). "Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir". The Pediatric Infectious Disease Journal. 39 (5): 435–437. doi:10.1097/INF.0000000000002584. PMID 32150007.

[8] Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR (September 2021). "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers". Antimicrobial Agents and Chemotherapy. 65 (10): e0102921. doi:10.1128/AAC.01029-21. PMC 8448163. PMID 34370575.

[9] Tomatis Souverbielle C, Erdem G, Sánchez PJ (June 2023). "Update on nonpolio enterovirus and parechovirus infections in neonates and young infants". Current Opinion in Pediatrics. 35 (3): 380–389. doi:10.1097/MOP.0000000000001236. PMID 36876331.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

See also

References